title: Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism.
abstract: Purpose. Secondary hyperparathyroidism with nodular hyperplasia is resistant to medical therapies. Cinacalcet is an effective treatment for severe secondary hyperparathyroidism. This multicentre retrospective study was designed to determine the long-term efficacy of cinacalcet in patients with nodular hyperplasia, the advanced type of parathyroid hyperplasia. Subjects and methods. The study subjects were 20 haemodialysis patients with secondary hyperparathyroidism. Patients with ultrasonographically confirmed large parathyroid glands (volume >0.5 cm(3)) were considered to have nodular hyperplasia (n = 8). Cinacalcet was started at the dose of 25 mg/day and titrated up to 100 mg/day to achieve the target intact-parathyroid hormone (iPTH) level of <250 pg/ml. Serum iPTH, corrected calcium, serum phosphorus, calcium × phosphorus product were measured and compared over the 48-week period of treatment with cinacalcet in all 20 patients and over 120 weeks in 6 of the patients (2 with nodular hyperplasia and 4 with non-nodular hyperplasia). We also examined the achievement rate of K/DOQI guideline treatment targets. The dosages of vitamin D preparation, sevelamer hydrochloride and calcium- containing phosphate binder were adjusted for the above target values. Results. iPTH levels were significantly lower at 48 weeks in both groups. However, corrected calcium levels, serum phosphorus levels and calcium phosphorus products were within the target values in the non-nodular hyperplasia group (n = 12), while the target value could not be achieved in the nodular hyperplasia group. In the long-term follow-up group, the levels of iPTH, corrected calcium, serum phosphorus and calcium × phosphorus products were significantly higher in nodular hyperplasia than in non-nodular hyperplasia. Conclusion. Our study suggests that cinacalcet lacks long-term efficacy in nodular hyperplasia, especially for controlling serum calcium and phosphorus levels.
authors.affiliation: Department of Nephrology, Akebono Clinic, Kumamoto.
authors.forename: Motoko
authors.initials: M
authors.lastname: Tanaka
authors.affiliation: Kidney Center , Toranomon Hospital , Minatoku, Tokyo.
authors.forename: Shohei
authors.initials: S
authors.lastname: Nakanishi
authors.affiliation: Division of Nephrology and Kidney Center , Kobe University School of Medicine , Kobe, Hyogo , Japan.
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Komaba
authors.affiliation: Department of Nephrology, Akebono Clinic, Kumamoto.
authors.forename: Kazuko
authors.initials: K
authors.lastname: Itoh
authors.affiliation: Department of Nephrology, Akebono Clinic, Kumamoto.
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Matsushita
authors.affiliation: Division of Nephrology and Kidney Center , Kobe University School of Medicine , Kobe, Hyogo , Japan.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Fukagawa
keywords: cinacalcet; haemodialysis; nodular hyperplasia; secondary hyperparathyroidism; ultrasonography